Himalayas-1: Rinzimetostat，一种别构 PRC2 抑制剂，+ Daro：🌎 3 期 RC，针对既往接受阿比特龙治疗的 mCRPC @urotoday #ESMO26 @quimmateo
📌n=600
📌1:1 随机分配至 rinzimetostat + Daro 对比 医生选择的 ARPI 或多西他赛
📌主要终点：rPFS
📌次要终点：OS
309 浏览 · 4 赞 · 5 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Zach Klaassen · x.com